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ABSTRACT
Introduction: The objective of this study was to
determine whether people with type 1 diabetes
are more likely to self-monitor their blood
glucose (SMBG) as recommended by their
diabetes health care professional using the
Accu-Chek MobileTM (F. Hoffmann-La Roche
AG, Basel, Switzerland) monitoring system
compared to the Freestyle OptiumTM (Abbott,
North Chicago, IL, USA).
Methods: Thirty-five participants with type 1
diabetes participating in a randomized cross-
over study were assigned to monitor their blood
glucose levels for a 3-month period using the
Accu-Chek Mobile or the Freestyle Optium
monitoring system and then to cross-over to
the alternative device. After completion of the
6-month cross-over period, participants were
invited to select their meter of choice and were
followed for a further 3 months.
Results: SMBG frequency increased in both
groups but participants monitored
significantly more often using the Accu-Chek
Mobile meter (frequency SMBG/week median:
19 vs. 10, P = 0.04). After 3 months using each
meter, 77% of participants indicated a
preference for the Accu-Chek Mobile meter.
Monitoring frequency in this group remained
higher than baseline during the 3-month post-
cross-over follow-up period.
Conclusion: Our results indicate that the Accu-
Chek Mobile meter improves SMBG frequency.
After experience of both systems, Accu-Chek
Mobile was the meter of choice for the majority
of participants in this study.
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INTRODUCTION
The findings of the Diabetes Control and
Complications Trial (DCCT) and Epidemiology
of Diabetes Interventions and Complications
(EDIC) studies have highlighted the importance
of maintaining glycemic control as close to
target as possible in people with type 1 diabetes
[1, 2]. However, such optimization is often
difficult to achieve. While intensive treatment
of type 1 diabetes has been made possible by
combining multiple daily injections (MDI) or
continuous subcutaneous insulin infusion
(CSII) with frequent self-monitoring of blood
glucose (SMBG), many people with type 1
diabetes only measure pre-meal blood glucose
levels, making decisions regarding insulin
therapy optimization difficult.
There are a number of reasons why people
with type 1 diabetes monitor less frequently
than recommended. For example, forgetfulness,
difficulties with handling and disposing of test
strips, lifestyle alignment (embarrassment of
monitoring in public, lack of time, and
difficulty monitoring away from home), as
well as the inability to make decisions based
on the results, have all been identified as major
barriers to appropriate SMBG [3–5]. To address
these issues, a novel, strip-free blood glucose
monitoring system has been developed, the
Accu-Chek MobileTM (F. Hoffmann-La Roche
AG, Basel, Switzerland). The Accu-Chek Mobile
incorporates a number of key features which
eliminate the need to handle test strips or single
lancets before and after use, giving the user
more freedom and flexibility when monitoring
blood glucose, as well as allowing more discrete
monitoring. The Accu-Chek Mobile device and
other similar integrated devices are estimated to
require 70% fewer steps in the performance of
SMBG and previous authors have speculated
that this is likely to improve SMBG compliance
[6]. The Accu-Chek Mobile device has also
performed well in patients’ hands, easily
reaching an international standard of accuracy
[7]. The Accu-Chek Mobile also allows the user
to set up to 10 reminder times; at each set time a
beep sounds and the reminder time is displayed.
A Danish survey of people with type 1 diabetes
found the Accu-Chek Mobile system improved
adherence to the recommended SMBG
frequency [3]. However, to date, there have
been no randomized-controlled trials to
determine whether the Accu-Chek Mobile
system is superior to other currently available
monitoring systems.
This randomized-controlled cross-over study
was designed to determine whether people with
type 1 diabetes are more likely to monitor their
diabetes as recommended by their diabetes
health care professional using the Accu-Chek
Mobile monitoring system compared to the
Freestyle OptiumTM (Abbott, North Chicago,
IL, USA), a system commonly used by people
with type 1 diabetes living in Australia. The
study also assessed the effect of the two
monitoring systems on peoples’ glycemic
control, diabetes treatment satisfaction,




This was a two-center, prospective, randomized
cross-over study conducted in two large
diabetes units on the Australian Eastern
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seaboard: the Royal Prince Alfred Hospital in
Sydney, and Eastern Health in Melbourne. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study after adequate explanation of the
aims, methods, anticipated benefits, and
potential hazards of the study.
Subjects were eligible to participate if they
were aged between 18 and 45 years, had type 1
diabetes diagnosed for one or more years, and
had a glycosylated hemoglobin
(HbA1c) C 7.5%. Subjects were also required to
be monitoring less frequently than
recommended by their health care professional
(i.e., monitoring on average fewer than three
times per day). Participants were excluded if
they had conditions that may influence blood
glucose monitoring behavior, such as
pregnancy or use of steroids.
After signing informed consent, subjects
were randomly assigned to one of two possible
monitoring sequences: (1) use of the Accu-Chek
Mobile system during the first 3 months of the
study, crossing over to use the Freestyle Optium
system during the second 3 months of the study
or, (2) use of the Freestyle Optium system
during the first 3 months, crossing over to use
the Accu-Chek Mobile system during the
second 3 months of the study. The primary
outcome of the study was frequency of SMBG
per week. Secondary outcomes included
glycemic control, satisfaction with treatment,
confidence in treating diabetes, and diabetes
distress, as well as meter preference.
Participants were required to attend three
study visits: baseline (Visit 1), 3 months (Visit
2), and 6 months (Visit 3). Where possible,
clinic and research visits were aligned to
minimize the participant’s attendance to the
study sites. At Visits 1 and 2 (baseline and
3 months) the participants were instructed on
the use of their assigned meter and they were
provided with sufficient supplies to monitor
their blood glucose levels up to eight times a
day for the following 3 months.
From Visit 2 onwards, the participant’s blood
glucose monitoring system (Accu-Chek Mobile
or Freestyle Optium) memory was downloaded
for assessment of monitoring frequency. The
memory capacity of each system is 500 and 450
measurements, respectively. Monitoring
frequency was calculated as (number of results
on the study meter/days of memory) 9 7.
Glycemic control was assessed using HbA1c.
HbA1c measured at the closest clinical
appointment was recorded at each study visit.
If the HbA1c had been measured more than
2 weeks prior to study visit, a finger prick
sample of blood was collected and an HbA1c
estimation was performed using a point of care
device (DCA Vantage Analyzer, Siemens AG,
Germany). Participants also completed a series
of validated questionnaires at enrolment. These
included the Diabetes Treatment Satisfaction
Questionnaire (DTSQ), status and change
measures (used under license) [4, 5], the
Confidence in Diabetes Self-Care (CIDS) scale
[8], and the Problem Areas in Diabetes
Management (PAID) scale [9].
At the completion of the cross-over study
participants were asked to select their study
meter of choice. They were also invited to
participate in a 3-month extension study.
Participants who chose to be involved in this
extension study were provided with sufficient
supplies to monitor their blood glucose levels
up to eight times a day for the following
3 months using their preferred meter. They
attended a fourth study visit scheduled
Diabetes Ther (2014) 5:557–565 559
9 months after their baseline visit and further
outcome data were collected as described above.
Data Analysis and Sample Size
The primary outcome was change in frequency
of monitoring from baseline. Using a two-sided
one-sample t test (a = 0.05), and assuming a
drop-out rate of 20%, a sample size of 23 was
determined to have 90% power to detect a
difference of at least 4 assessments/week with
an estimated standard deviation of 1.
Data were analyzed using the Number
Cruncher Statistical System (NCSS, LLC,
Kaysville, UT, USA) software. Each subject
acted as their own control; therefore, statistical
methods for paired data analysis including
paired t test, Wilcoxon signed-rank test, and
repeated measures analysis of variance were
adopted. Results were regarded as significant at
the P\0.05 level (two-tailed).
RESULTS
Forty people with type 1 diabetes were recruited
for the study; of these, five were lost to follow-
up. As shown in Table 1, the participants who
were lost to follow-up were younger than their
counterparts who completed the study. There
were no other differences in baseline profiles.
Monitoring frequency increased during both
of the 3-month cross-over periods but
participants monitored significantly more
often during the 3 months they were
randomized to use the Accu-Chek Mobile
meter (Table 2). There was no difference in
participants’ satisfaction or confidence in
managing diabetes using either monitoring
system. The choice of meter also did not
impact on the participants’ emotional
adjustment to living with diabetes as assessed
by the PAID scale. After 3 months of using both
monitoring systems, the majority of
participants (77%) indicated a preference for
the Accu-Chek Mobile meter.
As described previously, at completion of the
6-month randomized cross-over phase, all
participants were invited to be followed in a
3-month extension study. Only two
participants did not continue into this
extension phase: one withdrew due to
pregnancy and the other withdrew as their
work required them to move inter-state. The
monitoring frequency of the participants who
indicated a preference for the Accu-Chek
Mobile meter (n = 25) remained significantly
higher during the 3-month extension phase
than at baseline [median 17 [interquartile range
(IQR) 8–29] SMBG estimates/week vs. median: 7
(IQR: 3–16) SMBG estimates/week; P = 0.0002].
These participants also had a small but
statistically significant improvement in their
glycemic control [average HbA1c: 8.7 ± 1.1 %
(70.1 ± 11.3 mmol/mol) at 9 months vs.
9.1 ± 1.2% (75.3 ± 13.3 mmol/mol) at
baseline; P = 0.04]. There was no change in
monitoring frequency or glycemic control for
those participants who indicated a preference
for the Freestyle Optium meter (n = 8);
however, these participants were monitoring
more frequently at baseline (median 18 [IQR:
12–28] SMBG estimates/week). They also had a
lower baseline average HbA1c [8.6 ± 1.1%
(70 ± 15.1 mmol/mol)].
DISCUSSION
The DCCT [1, 2] and EDIC [1, 2] trials
demonstrated that intensive glycemic control
in type 1 diabetes led to a reduced incidence of
microvascular and macrovascular complications
in the long term. An essential component of
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intensified insulin therapy, whether by MDI or
CSII, is regular SMBG to enable accurate
adjustment of insulin to correct both fasting
and post-prandial glucose levels. Despite this,
compliance with SMBG is poor with up to 24%
of persons with type 1 diabetes testing less than
once weekly. Predictors of poor compliance
include male gender, younger age, living
alone, low diabetes-related concern, and
cigarette smoking [10]. High frequency of
monitoring has been associated with lower
HbA1c and reduced incidence of
hypoglycemia, although in some studies
recent hypoglycemia was associated with
increased monitoring frequency [10–12]. In a
study by Schu¨tt et al. [12], HbA1c was reduced
by 0.32% per extra test done per day in people
with type 1 diabetes on 4 injections per day or
CSII, similar to the participants in our study.
One study has related SMBG to long-term
complications and has suggested that higher
frequencies of monitoring are associated with
reduced HbA1c variability and reduced
microvascular complications [13].
Other barriers to SMBG include invasiveness.
In a study examining the impact of the person’s
perception of the invasiveness of the SMBG
technique [14], 63% of respondents reported
invasiveness was a reason for skipping tests. A
semi-quantitative measure of perceived
invasiveness correlated negatively with testing
frequency [14]. Although there are no published
data, the authors were of the opinion that this
invasiveness extends beyond the lancet but
includes the degree to which the SMBG
technique and equipment impact on lifestyle
and cause embarrassment through being
socially visible. The Accu-Chek Mobile system
used in this study has potential advantages in
having a connected lancet device and a strip-
less system utilizing a flexible strip contained
within a cartridge. These features make the
device potentially simpler to use and removed
the need to deal with waste strips. Our
Table 1 Baseline demographic and clinical proﬁle for participants completing the study compared to those lost to follow-up
Characteristic Lost to follow-up (N5 5) Completed the study (N5 35)
Age (years)a 22.8 (1.8) 32.7 (10.3)
Duration (years)b 13 (6–18) 18 (7–25)
Males (%) 60 43
Frequency of SMBG per weekc 6 (3–8) 10 (3–19)
HbA1c (%) 8.9 (2.2) 9.1 (1.4)
HbA1c (mmol/mol) 76.6 (24.3) 75.8 (15.4)
Sum CIDS score 87.2 (12.8) 86.5 (13.4)
CIDS scoreb 68.6 (10.0–78.9) 54.3 (22.9–74.3)
PAID score 24.4 (5.9) 27.6 (19.4)
DTSQ score 26.2 (6.8) 26.1 (6.2)
CIDS conﬁdence in diabetes self-care scale, DTSQ diabetes treatment satisfaction questionnaire, HbA1c glycosylated
hemoglobin, PAID problem areas in diabetes management, SMBG self-monitoring of blood glucose
Results expressed as mean (SD) unless otherwise indicated
a t = 2.1, P = 0.04
b Median (range) or c median (IQR)
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comparator, the Freestyle Optium system, was
amongst the most popular meters at the time in
Australia [15] and uses a conventional blood
glucose testing strip that needs to be inserted in
the device and disposed of afterwards.
Approaches to increase monitoring
frequency have included addressing access and
cost issues [16] and some have suggested the
importance of linguistically and culturally
appropriate education [17]. A 12-week
behavioral change program consisting of a
course on self-control behavior techniques was
effective in increasing SMBG frequency but did
not result in achieved SMBG goals [18]. The
sustainability of such techniques has not been
tested. Meter features have been examined as a
determinant of SMBG frequency. In one study
the education of people to use the advanced
features of a meter, including an audible
reminder, increased the frequency of SMBG
[19]. With regards to the Accu-Chek Mobile
meter system, one previous study has
demonstrated an increased compliance with
recommended SMBG frequency [3]. In this
study of over 1,000 non-compliant patients
with type 1 diabetes, 3 months of Accu-Chek
Mobile use increased testing frequency from
8.2 tests per week to 18.4 tests per week (goal:
21 tests per week) [3]; this was, however, an
uncontrolled and non-randomized study.
We designed a study to examine the effect of
two blood glucose monitoring systems on
SHBM frequency in a prospective, randomized
cross-over study. The primary outcome of the
study was the number of SMBG estimations per
week. Secondary outcomes included glycemic
control, satisfaction with treatment, confidence
in treating diabetes, and diabetes distress. Meter
preference was assessed at the end of the
6-month cross-over study by allowing the
subjects to choose the meter they would use
for the final 3 months of the study. The
advantages of the design were that subjects
were able to experience each of the meters in
turn and then express a preference, while the
cross-over design ensured that any effect for the
order of exposure was controlled for by the
randomization.
Table 2 Monitoring frequency (SMBG/week), glycemic control (HbA1c), satisfaction with treatment (DTSQ), conﬁdence
in treating diabetes (CIDS score), and diabetes distress (PAID score) at baseline and during the 3-month cross-over periods
that participants were randomized to use the Accu-Chek MobileTM meter vs. the Freestyle OptiumTM meter
Characteristic Baseline N5 35 Accu-Chek MobileTM N5 35 Freestyle OptiumTM N5 35
Frequency SMBG/weeka,b 10 (3–19) 19 (9–25) 12 (7–26)
HbA1c (%) 9.1 (1.4) 8.9 (1.3) 8.7 (1.3)
HbA1c (mmol/mol) 75.7 (15.4) 72.8 (13.3) 71.8 (13.2)
DTSQs 26.1 (6.2) 26.2 (6.8) 28.4 (6.7)
DTSQca – 10 (0–15) 10 (-2–14)
CIDS score 86.5 (13.4) 87.0 (9.9) 86.3 (11.6)
PAID score 27.6 (19.4) 24.6 (17.5) 29.3 (21.7)
CIDS conﬁdence in diabetes self-care scale, DTSQs diabetes treatment satisfaction questionnaire (status version), DTSQc
diabetes treatment satisfaction questionnaire (change version), HbA1c glycosylated hemoglobin, PAID problem areas in
diabetes management, SMBG self-monitoring of blood glucose
Results expressed as mean (SD) or a median (IQR)
b F = 6.2, P = 0.003
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Our results indicated that, while all subjects
increased their monitoring frequency, persons
using the Accu-Chek Mobile system tested more
frequently than those using the Freestyle
Optium system, and that the majority of
patients preferred the Accu-Chek Mobile
system. There was no effect of SMBG system
on satisfaction and confidence in diabetes
treatment or in diabetes-related distress. It is
likely, therefore, that the change in SMBG
frequency was due to ease of use of the device
rather than any change in attitude or more
general compliance within the cohort.
Seventy-seven percent of subjects chose to
use the Accu-Chek Mobile meter during the
3-month extension period. At the end of
9 months, these subjects had a lower average
HbA1c (9.1% vs. 8.7%) although they will have
used the Freestyle Optium meter for 3 months
of the total period. Subjects that chose the
Freestyle Optium meter had lower HbA1c at
baseline but the numbers in this group were
too small to make meaningful comment on the
effect of this meter choice on HbA1c over
9 months. Although HbA1c improved during
the 3-month cross-over phase of the study
there were no significant differences between
groups.
Potential sources of bias in our study include
previous exposure to one or other of the meters.
Subjects came into the study using a variety of
meters and some will have been using the
Freestyle Optium meter. None were using the
Accu-Chek Mobile meter. It is possible that
some will have preferred the Accu-Chek Mobile
meter simply because of its newness, although
the cross-over design helps to mitigate against
this. Necessarily, our study was unblinded to
both subject and investigator. Investigators
took care to avoid expressing bias to one or
other meter and all study documentation
treated the meters as equal comparators.
CONCLUSION
The Accu-Chek Mobile blood glucose
monitoring system confers an advantage over
a popular comparator system through
increasing the frequency of SMBG. Although
not demonstrated in this study, this has
potential benefits for glycemic control and
reducing long-term complications.
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